NasdaqGS:JAZZPharmaceuticals
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Oncology Data, Cannabis Shift And Modeyso Royalty News
Jazz Pharmaceuticals (JAZZ) is back on investors’ radar after a cluster of developments, including upcoming late-stage oncology data at ASCO 2026, evolving U.S. cannabis policy and a new royalty deal tied to Modeyso.
See our latest analysis for Jazz Pharmaceuticals.
Those oncology updates at ASCO 2026, the U.S. move toward cannabis rescheduling and fresh headlines around Modeyso royalties arrive as Jazz’s share price sits at US$199.96, with a 30 day share price return of 8.08% and a 1 year...